Philippe Aftimos, MD

Philippe Aftimos, MD is a medical oncologist and the clinical trials development leader at the Clinical Trials Conduct Unit of Institut Jules Bordet, a comprehensive cancer center in Brussels.

Dr. Aftimos works in the fields of breast cancer, new medicine development, and precision medicine. At Institut Jules Bordet, he heads the new drug development program at the Clinical Trials Conduct Unit. He has participated in the development of novel monoclonal antibodies and antibody-drug conjugates for the treatment of breast cancer as well as in the development of novel endocrine therapies. He currently leads multiple projects with agents targeting epigenetics. As a clinical research physician, he is a member of the think tank of the Oncodistinct network and is vice-chair of the Scientific Executive Committee of the International Breast Cancer Study Group.

In the precision medicine field, Dr. Aftimos has participated in drafting the national Belgian NGS guidelines. He is co-primary investigator of AURORA (Aiming to Understand the Molecular Aberrations of Metastatic Breast Cancer), a large European molecular screening program launched by the Breast International Group.  He is also co-primary investigator of the Belgian Society of Medical Oncology precision medicine program, a national clinico-genomic data sharing program.

Dr Aftimos is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the European Society of Medical Oncology and the Belgian Society of Medical Oncology. He has authored and co-authored more than 50 peer-reviewed articles.